Pro-Tect Pharmaceuticals said that the acquired patents would enable it to provide efficient, effective drug delivery platforms for three essential needs i.e., a gastro-retentive platform for drugs that otherwise have short time windows for absorption.

It also includes an abuse deterrent platform for prescription drugs that are prone to abuse, especially narcotic pain-killers and a once-daily platform that allows two or more drugs commonly taken in combination to be delivered via a single dose with fewer side effects.

Pro-Tect Pharmaceuticals plans to proceed with a program to develop and commercialise once-daily drugs for diabetic neuropathic pain, fibromyalgia, postherpetic neuralgia and epilepsy.

Pro-Tect Pharmaceuticals also plans to develop and commercialise once-daily opioid combinations as well as abuse-deterrent opioid combinations for moderate to severe pain. This patents acquisition includes a pain project that is already under discussion for a potential licensing agreement with a multinational pharmaceutical manufacturer.

Bill Abajian, CEO of Pro-Tect Pharmaceuticals, said: "It's incredible to us that no one previously has developed delivery platforms that meet such obvious and crucial needs. In particular, the ability to treat long-term pain without patients becoming opioid-addicted would fundamentally change pain management. We're excited that the success of these drug delivery platforms could not just improve the quality of life for so many people, but actually save lives."

Source: web of PBR